HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate revises restructuring expectations

This article was originally published in The Rose Sheet

Executive Summary

The 2004 Restructuring Program is progressing on schedule, Colgate-Palmolive execs say during April 25 first-quarter analyst call. Announced in December 2004, the four-year restructuring program was expected to deliver ongoing savings of $250 mil. to $300 mil. after tax, annually, by 2008 (1"The Rose Sheet" Dec. 13, 2004, p. 4). However, the company has since identified additional savings projects that allow the firm to save an additional $50 million after-tax, execs note. Consequently, the company has revised its savings projections, now saying the program will result in $300 mil. to $350 mil. in savings after-tax. Colgate adds that it plans to obtain these additional savings without extending the length of the program beyond its anticipated completion date of Dec. 31, 2008...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel